^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Hodgkin Lymphoma
    Regimen:Bv-AVE-PC (Adcetris (brentuximab vedotin) + cyclophosphamide + doxorubicin hydrochloride + etoposide IV + + vincristine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    01/12/2023
    Excerpt:
    CLINICAL PRESENTATION: CHL...PRIMARY TREATMENT….Preferred...Bv-AVE-PC x 2 cycles (category 1) (AHOD1331)….Bv-AVE-PC regimen added for High Risk CHL (AHOD1331).
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO 2022
    Title:

    Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children's Oncology Group phase 3 study AHOD1331 (NCT 02166463)

    Published date:
    05/26/2022
    Excerpt:
    Brentuximab vedotin with AVE-PC in a dose intensive regimen has superior efficacy to ABVE-PC for pediatric patients with high-risk HL.
    DOI:
    10.1200/JCO.2022.40.16_suppl.7504
    Trial ID:
    AHOD1331